Respiratory inhaler devices market seen reaching $64.74 billion by 2030

The Business Research Company says the global respiratory inhaler devices market is set to grow from $47.09 billion in 2026 to $64.74 billion by 2030, driven by rising asthma and COPD cases, smart inhalers and wider access in emerging markets. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - The respiratory inhaler devices market is tied to treatment for asthma, COPD and other breathing disorders. - Faster growth in smart inhalers, nebulizers and targeted drug delivery could improve medication adherence and outcomes for patients. - Rising respiratory disease prevalence is expanding demand for portable devices that deliver medicine directly to the lungs.

What happened: - The Business Research Company released its Respiratory Inhaler Devices Market Report 2026 covering market size, trends and global forecasts for 2026-2035. - The report says the market grew from $43.98 billion in 2025 to $47.09 billion in 2026, a 7.1% CAGR. - The market is projected to reach $64.74 billion by 2030, with an 8.3% CAGR. - The report was published Aug. 28, 2026. - A free sample of the report is available. - The full report is also available online.

The details: - Respiratory inhaler devices are compact, portable instruments that deliver medication directly to the lungs. - The devices are designed to minimize systemic drug exposure and provide rapid relief during asthma attacks or COPD exacerbations. - Growth in the past several years has been driven by the rising prevalence of asthma and COPD worldwide. - The market has also benefited from broader use of inhalers for acute symptom relief and maintenance therapy. - Early use of chlorofluorocarbon and hydrofluoroalkane metered dose inhalers helped shape the market. - Expansion in respiratory care services at hospitals and clinics has supported demand. - Greater awareness of targeted pulmonary drug delivery has added momentum. - The report cites growing demand for digitally enabled and smart inhalers as a key driver through 2030. - Mesh and ultrasonic nebulizers are expected to see increased use. - The report points to rising treatment volumes among chronic respiratory disease patients. - Broader access to inhaler therapies in emerging healthcare markets is expected to support growth. - Efforts to improve medication adherence and therapeutic outcomes are another growth factor. - U.S. Centers for Disease Control and Prevention data released in November 2024 showed respiratory disease prevalence rising to 25 million cases in 2024 from 22 million in 2022.

Between the lines: - The forecast implies inhaler makers are moving from a volume market to a technology-driven market. - Smart-device features and adherence tools appear to be becoming as important as the medication-delivery hardware itself. - The regional split suggests mature markets still dominate revenue, while developing markets will likely drive the next wave of unit growth.

What's next: - North America is expected to remain the largest regional market through the near term. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report includes new analytical tools such as market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables. - Contact details provided in the release include Saumya Sahay at marketing@tbrc.info and the company’s listed phone numbers.

The bottom line: - The inhaler-device market is expected to keep expanding quickly as respiratory disease rates rise and smarter delivery technologies gain traction.